JPH09504030A - Cntf族アンタゴニスト - Google Patents
Cntf族アンタゴニストInfo
- Publication number
- JPH09504030A JPH09504030A JP7512169A JP51216995A JPH09504030A JP H09504030 A JPH09504030 A JP H09504030A JP 7512169 A JP7512169 A JP 7512169A JP 51216995 A JP51216995 A JP 51216995A JP H09504030 A JPH09504030 A JP H09504030A
- Authority
- JP
- Japan
- Prior art keywords
- cntf
- mutant
- molecule
- complex
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.サイトカインレセプターの可溶性α特異性決定成分とサイトカインレセプタ ーの可溶性β1成分とを含んでなるsRα:β1ヘテロ二量体タンパク質。 2.サイトカインがCNTF族サイトカインのメンバーである請求項1に記載の タンパク質。 3.前記β1レセプターがgp130である請求項1に記載のタンパク質。 4.前記β1レセプターがLIFRβである請求項1に記載のタンパク質。 5.サイトカインがCNTFであり、前記αレセプターがsCNTFRαであり 、前記β1レセプターがgp130である請求項2に記載のタンパク質。 6.サイトカインがIL−6であり、前記αレセプターがsIL−6Rαであり 、前記β1レセプターがgp130である請求項2に記載のタンパク質。 7.前記IL−6がIL−6Rα及び第1のgp130分子と錯体形成するとき に第2のgp130分子とは結合できないようにするβ2突然変異を含むIL− 6タンパク質。 8.前記CNTFがCNTFRα及びgp130と錯体形 成するときにLIFRβとは結合できないようにするβ2突然変異を含むCNT Fタンパク質。 9.1)IL−6産生クローンを製造し; 2)ランダム又は標的突然変異生成を用いて上記クローンを突然変異させて突然 変異体IL−6を発現するサブクローンを産生し; 3)サブクローンによって産生された突然変異体IL−6分子を回収し; 4)IL−6Rα及び第1のgp130分子と錯体形成したときに第2のgp1 30とは結合し得ない突然変異IL−6分子をIL−6アンタゴニストとして同 定する ことからなるIL−6アンタゴニストの単離方法。 10.前記同定が、 i)突然変異IL−6分子にIL−6Rα:β1ヘテロ二量体を加えてIL−6 /IL−6Rα:β1中間体を形成し; ii)前記中間体に検出可能gp130を加えてIL−6:IL−6Rα:β1: β2錯体を形成し; iii)IL−6:IL−6Rα:β1:β2錯体中の検出可能gp130の量を 測定することによって前記検出可能g p130と前記IL−6/αβ1中間体との結合を調べることからなる請求項9 に記載の方法。 11.1)IL−6産生クローンを製造し; 2)ランダム又は標的突然変異生成を用いて上記クローンを突然変異させて突然 変異体IL−6を発現するサブクローンを産生し; 3)突然変異IL−6分子を発現し; 4)前記突然変異IL−6分子をIL−6Rαと合わせてIL−6/IL−6R α錯体を形成し; 5)前記IL−6/IL−6Rα錯体に検出可能gp130を加え; 6)前記IL−6/IL−6Rα錯体中に存在するときに前記検出可能gp13 0とは結合し得ない前記突然変異IL−6分子をIL−6アンタゴニストとして 同定する ことからなるIL−6アンタゴニストの単離方法。 12.1)CNTF産生クローンを製造し; 2)ランダム又は標的突然変異生成を用いて上記クローンを突然変異させて突然 変異体CNTFを発現するサブクローンを産生し; 3)サブクローンによって産生された突然変異体CNTF 分子を回収し; 4)CNTFRα及びgp130と錯体形成したときにLIFRβとは結合し得 ない突然変異CNTF分子をCNTFアンタゴニストとして同定する ことからなるCNTFアンタゴニストの単離方法。 13.前記同定が、 i)突然変異CNTF分子にCNTFRα:β1ヘテロ二量体を加えてCNTF /CNTFRα:β1中間体を形成し; ii)前記中間体に検出可能LIFRβを加えてCNTF:CNTFRα:β1: β2錯体を形成し; iii)CNTF:CNTFRα:β1:β2錯体中の検出可能LIFRβの量を 測定することによって前記検出可能LIFRβと前記CNTF/αβ1中間体と の結合を調べることからなる請求項12に記載の方法。 14.1)CNTF産生クローンを製造し; 2)ランダム又は標的突然変異生成を用いて上記クローンを突然変異させて突然 変異体CNTFを発現するサブクローンを産生し; 3)突然変異CNTF分子を発現し; 4)前記突然変異CNTF分子をCNTFRαと合わせてCNTF/CNTFR α錯体を形成し; 5)前記CNTF/CNTFRα錯体に検出可能gp130を加え; 6)前記CNTF/CNTFRα錯体中に存在するときに前記検出可能gp13 0とは結合し得ないCNTF分子をCNTFアンタゴニストとして同定する ことからなるCNTFアンタゴニストの単離方法。 15.請求項1から8のいずれか一項に記載のタンパク質をコードするDNA配 列。 16.上記で特記した請求項1、7及び8のいずれか一項に記載のタンパク質。 17.請求項1から8及び16のいずれか一項に記載のタンパク質と医薬的に許 容可能なキャリヤーとを含んでなる医薬組成物。 18.請求項6又は7に記載のタンパク質と医薬的に許容可能なキャリヤーとを 含んでなるIL−6関連疾病又は障害の治療用医薬組成物。 19.エストロゲン欠失患者の骨粗鬆症の治療方法で使用するための請求項6又 は7に記載のタンパク質。 20.患者の多発性骨髄腫の治療方法で使用するための請求項6又は7に記載の タンパク質。 21.患者のカヘキシーの治療方法で使用するための請求項6又は7に記載のタ ンパク質。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/140,222 US5470952A (en) | 1993-10-20 | 1993-10-20 | CNTF and IL-6 antagonists |
US08/140,222 | 1993-10-20 | ||
PCT/US1994/011873 WO1995011303A1 (en) | 1993-10-20 | 1994-10-19 | Cntf family antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504030A true JPH09504030A (ja) | 1997-04-22 |
JP3961562B2 JP3961562B2 (ja) | 2007-08-22 |
Family
ID=22490270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51216995A Expired - Fee Related JP3961562B2 (ja) | 1993-10-20 | 1994-10-19 | Cntf族アンタゴニスト |
Country Status (16)
Country | Link |
---|---|
US (2) | US5470952A (ja) |
EP (1) | EP0726954B2 (ja) |
JP (1) | JP3961562B2 (ja) |
CN (1) | CN1138350A (ja) |
AT (1) | ATE187982T1 (ja) |
AU (1) | AU679579B2 (ja) |
CA (1) | CA2173846C (ja) |
DE (1) | DE69422304T3 (ja) |
DK (1) | DK0726954T4 (ja) |
ES (1) | ES2139759T5 (ja) |
GR (1) | GR3032777T3 (ja) |
HK (1) | HK1008346A1 (ja) |
IL (1) | IL111324A0 (ja) |
PT (1) | PT726954E (ja) |
WO (1) | WO1995011303A1 (ja) |
ZA (1) | ZA948242B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7229962B2 (en) | 2001-07-26 | 2007-06-12 | Medexgen Co., Ltd. | Tetravalent etanercept |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728536A (en) * | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
AU687763B2 (en) * | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
IT1261787B (it) * | 1993-06-23 | 1996-06-03 | Angeletti P Ist Richerche Bio | Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130. |
US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
AUPN024994A0 (en) * | 1994-12-23 | 1995-01-27 | Ludwig Institute For Cancer Research | Assay and peptides for use therein |
US7070783B1 (en) * | 1995-05-09 | 2006-07-04 | The Mathilda And Terence Kennedy Institute Of Rheumatology | Small molecular weight TNF receptor multimeric molecule |
US6217858B1 (en) * | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
AU3668897A (en) * | 1996-07-17 | 1998-02-09 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
GB9621095D0 (en) * | 1996-10-09 | 1996-11-27 | Imperial College | Novel system |
IT1288388B1 (it) * | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
US6046158A (en) * | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
SE9701010D0 (sv) | 1997-03-19 | 1997-03-19 | Pharmacia & Upjohn Ab | Antibody |
DE69839992D1 (de) | 1997-03-21 | 2008-10-23 | Chugai Pharmaceutical Co Ltd | Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff |
AU737592B2 (en) | 1998-01-23 | 2001-08-23 | Immunex Corporation | Il-18 receptors |
US6410245B1 (en) * | 1998-04-01 | 2002-06-25 | Affymax, Inc. | Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US7083949B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
US6864359B1 (en) * | 1999-02-11 | 2005-03-08 | Xencor | Structure-based screening techniques for drug discovery |
AU3873200A (en) * | 1999-03-11 | 2000-09-28 | Schering Corporation | Mammalian cytokines; related reagents and methods |
US6800460B1 (en) | 1999-03-11 | 2004-10-05 | Schering Corporation | Mammalian cytokine complexes |
US6673771B1 (en) | 1999-07-28 | 2004-01-06 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclast activity |
US6682739B1 (en) * | 1999-07-28 | 2004-01-27 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting osteoclastogenesis |
EP1221963A4 (en) * | 1999-07-28 | 2006-03-22 | Univ Pennsylvania | METHODS OF INHIBITING OSTEOCLASTOGENESIS |
AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
EP1226173A1 (en) * | 1999-10-07 | 2002-07-31 | Maxygen Aps | Single-chain antagonist polypeptides |
WO2002064021A2 (en) * | 2001-02-12 | 2002-08-22 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity |
US6864047B2 (en) * | 2001-03-29 | 2005-03-08 | Mayo Foundation For Medical Education And Research | IL1-β: a new target for myeloma therapy |
JP4133344B2 (ja) * | 2001-04-23 | 2008-08-13 | 輝行 長棟 | レポーター(標識)分子間相互作用を利用した分析方法 |
ES2527471T3 (es) | 2001-05-11 | 2015-01-26 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
US20030125251A1 (en) * | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
WO2003018797A2 (en) * | 2001-08-22 | 2003-03-06 | Helix Biopharma Corporation | Method and device for integrated protein expression, purification and detection |
EP1542719A4 (en) | 2001-12-05 | 2006-06-21 | Baylor College Medicine | METHODS AND COMPOSITIONS FOR REGULATING OS FORMATION BY MODULATING THE SYMPATHETIC TONUS |
EP1545578A4 (en) | 2002-08-28 | 2010-07-07 | Immunex Corp | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES |
ATE496066T1 (de) * | 2002-10-25 | 2011-02-15 | Us Gov Health & Human Serv | Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta |
FI20031050A (fi) * | 2003-07-09 | 2005-01-10 | Valtion Teknillinen | Menetelmä proteiinien katkaisuun |
US20050069987A1 (en) * | 2003-09-30 | 2005-03-31 | Daly Thomas J. | Modified ciliary neurotrophic factor polypeptides with reduced antigenicity |
EP1682584B1 (en) * | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
US8591885B2 (en) | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US20050244472A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
US7786261B2 (en) * | 2004-09-02 | 2010-08-31 | National Research Council Of Canada | Coiled-coil fusion proteins comprising cell receptor domains |
AU2006214052A1 (en) * | 2005-02-17 | 2006-08-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synergistic effect of TGF-beta blockade and immunogenic agents on tumors |
US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
US7889347B2 (en) | 2005-11-21 | 2011-02-15 | Plexera Llc | Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism |
US7463358B2 (en) | 2005-12-06 | 2008-12-09 | Lumera Corporation | Highly stable surface plasmon resonance plates, microarrays, and methods |
AU2006332533A1 (en) * | 2005-12-30 | 2007-07-12 | Pharmaessentia Corp. | Drug-polymer conjugates |
WO2008008373A2 (en) | 2006-07-11 | 2008-01-17 | Arubor Corp | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
JP2010500360A (ja) | 2006-08-10 | 2010-01-07 | アルボア コーポレーション | 炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法 |
EP2578684B1 (en) | 2007-03-19 | 2016-02-24 | National Research Council Of Canada | Antagonists of ligands and uses thereof |
US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
US8004669B1 (en) | 2007-12-18 | 2011-08-23 | Plexera Llc | SPR apparatus with a high performance fluid delivery system |
US8658135B2 (en) * | 2008-03-19 | 2014-02-25 | National Research Council Of Canada | Antagonists of ligands and uses thereof |
DK2920201T3 (da) | 2012-11-15 | 2020-04-14 | Apellis Pharmaceuticals Inc | Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder |
US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
CN116655801A (zh) | 2013-08-22 | 2023-08-29 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
WO2017024171A1 (en) | 2015-08-04 | 2017-02-09 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
CN117503905A (zh) | 2015-10-07 | 2024-02-06 | 阿佩利斯制药有限公司 | 给药方案 |
MX2019012033A (es) | 2017-04-07 | 2019-12-05 | Apellis Pharmaceuticals Inc | Regímenes de dosificación y composiciones y métodos relacionados. |
WO2018204594A1 (en) | 2017-05-04 | 2018-11-08 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
CR20200392A (es) | 2018-03-09 | 2020-11-17 | Agenus Inc | Anticuerpos anti-cd73 y métodos de uso de los mismos |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5262522A (en) * | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JP3255699B2 (ja) * | 1992-04-23 | 2002-02-12 | 味の素株式会社 | ヒトIL−2レセプターγ鎖分子 |
US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
-
1993
- 1993-10-20 US US08/140,222 patent/US5470952A/en not_active Expired - Lifetime
-
1994
- 1994-10-18 IL IL11132494A patent/IL111324A0/xx unknown
- 1994-10-19 DE DE69422304T patent/DE69422304T3/de not_active Expired - Lifetime
- 1994-10-19 WO PCT/US1994/011873 patent/WO1995011303A1/en active IP Right Grant
- 1994-10-19 AU AU79827/94A patent/AU679579B2/en not_active Ceased
- 1994-10-19 EP EP94930818A patent/EP0726954B2/en not_active Expired - Lifetime
- 1994-10-19 JP JP51216995A patent/JP3961562B2/ja not_active Expired - Fee Related
- 1994-10-19 PT PT94930818T patent/PT726954E/pt unknown
- 1994-10-19 DK DK94930818T patent/DK0726954T4/da active
- 1994-10-19 ES ES94930818T patent/ES2139759T5/es not_active Expired - Lifetime
- 1994-10-19 AT AT94930818T patent/ATE187982T1/de active
- 1994-10-19 CN CN94194575A patent/CN1138350A/zh active Pending
- 1994-10-19 CA CA002173846A patent/CA2173846C/en not_active Expired - Fee Related
- 1994-10-20 ZA ZA948242A patent/ZA948242B/xx unknown
-
1995
- 1995-11-27 US US08/563,105 patent/US5844099A/en not_active Expired - Lifetime
-
1998
- 1998-07-15 HK HK98109176A patent/HK1008346A1/xx not_active IP Right Cessation
-
2000
- 2000-02-28 GR GR20000400479T patent/GR3032777T3/el unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7229962B2 (en) | 2001-07-26 | 2007-06-12 | Medexgen Co., Ltd. | Tetravalent etanercept |
US7670602B2 (en) | 2001-07-26 | 2010-03-02 | Medexgen Co., Ltd | Concatameric immunoadhesion molecule |
US8372961B2 (en) | 2001-07-26 | 2013-02-12 | Medexgen Co., Ltd. | Polynucleotides encoding concatameric immunoadhesion molecules |
Also Published As
Publication number | Publication date |
---|---|
GR3032777T3 (en) | 2000-06-30 |
WO1995011303A1 (en) | 1995-04-27 |
CN1138350A (zh) | 1996-12-18 |
US5470952A (en) | 1995-11-28 |
ATE187982T1 (de) | 2000-01-15 |
DK0726954T3 (da) | 2000-05-01 |
EP0726954A1 (en) | 1996-08-21 |
IL111324A0 (en) | 1994-12-29 |
ES2139759T5 (es) | 2007-11-16 |
CA2173846A1 (en) | 1995-04-27 |
AU679579B2 (en) | 1997-07-03 |
DE69422304D1 (de) | 2000-01-27 |
PT726954E (pt) | 2000-04-28 |
CA2173846C (en) | 2009-01-27 |
ES2139759T3 (es) | 2000-02-16 |
JP3961562B2 (ja) | 2007-08-22 |
DE69422304T3 (de) | 2007-12-27 |
AU7982794A (en) | 1995-05-08 |
EP0726954B1 (en) | 1999-12-22 |
US5844099A (en) | 1998-12-01 |
ZA948242B (en) | 1995-06-13 |
EP0726954B2 (en) | 2007-05-30 |
DK0726954T4 (da) | 2007-10-01 |
HK1008346A1 (en) | 1999-05-07 |
DE69422304T2 (de) | 2000-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09504030A (ja) | Cntf族アンタゴニスト | |
JP3415162B2 (ja) | Il―13受容体ポリペプチド | |
US6610513B2 (en) | Receptor proteins | |
JPH07509613A (ja) | インターロイキン−10(il−10)のための哺乳類レセプター | |
JPH10179178A (ja) | ヒト7回膜貫通型レセプター | |
JP2002504818A (ja) | リガンドファミリーのntn−2メンバー | |
JP2003508088A (ja) | 52個のヒト分泌タンパク質 | |
JP2002532083A (ja) | 47個のヒト分泌タンパク質 | |
JP2000505420A (ja) | サイトカインアンタゴニストおよびアゴニスト | |
JP2001512667A (ja) | ヒトオーファンレセプターntr−1 | |
US6248554B1 (en) | DNA sequence coding for a BMP receptor | |
JP2002530062A (ja) | 12個のヒト分泌タンパク質 | |
JP2002500633A (ja) | Edg−1様受容体 | |
Heller et al. | Analysis of function and expression of the chick GPA receptor (GPAR α) suggests multiple roles in neuronal development | |
JP2002540763A (ja) | 33個のヒト分泌タンパク質 | |
JP3266611B2 (ja) | 毛様体神経栄養因子レセプター | |
JP2002543764A (ja) | 46個のヒト分泌タンパク質 | |
JP2002530058A (ja) | 31個のヒト分泌タンパク質 | |
JP4694580B2 (ja) | ヒトおよび哺乳動物の幹細胞由来神経生存因子 | |
KR20010043090A (ko) | 신규인 폴리펩티드, 그 폴리펩티드를 코드화하는 cDNA및 그 용도 | |
JP2002509693A (ja) | カドヘリン由来成長因子及びその使用 | |
US20020164785A1 (en) | Novel orphan receptors | |
JP2001527418A (ja) | グリア細胞系由来の神経栄養因子レセプター | |
JP2002538810A (ja) | 50個のヒト分泌タンパク質 | |
US6207413B1 (en) | Nucleic acids encoding novel orphan cytokine receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040518 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070316 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070409 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070517 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |